Where to go from here?
Reaching the five year point since first diagnosis is a big milestone for breast cancer patients. However the threat of breast cancer returning continues to cast a shadow over the lives of women and their families. The five year landmark is also an important crossroads, particularly for women taking tamoxifen when after five years, the risks outweigh the benefits of continuing treatment. Modern day advancements continue to throw women lifelines, lowering the risk of breast cancer recurrence, making the five year mark a time to reflect on future treatment decisions.
So what are the options after five years of tamoxifen?
- Switching to a different therapy regime.
- Seeking alternative and complementary medication.
- Stopping treatment all together.
It is extremely important to think about these different options before making a decision on how your treatment should progress. Talk to your GP/oncologist about these options, or alternatively, you can seek advice from Patient Support Groups. |
Five facts for Five years on
1 |
In the UK five year survival rates are increasing; in the early 1970s, half of all women with breast cancer were successfully treated. This has increased dramatically over the last few decades to 8 in 10 women surviving today.1 |
2 |
There is still a significant and long-term chance that breast cancer will return in women who have completed five years of tamoxifen treatment.2, 3 |
3 |
More than half of all cancers which return occur after women have received five years of tamoxifen therapy.1,4 |
4 |
Even ten years after treatment, the risk of cancer returning still exists.3 |
5 |
1 in 4 post-menopausal women who have survived past five years of breast cancer claim to not know if the risk of recurrence is higher for them than other breast cancer patients. |
 |
 |

References:
1. Cancer Research UK: http://www.cancerhelp.org.uk/
help/default.asp?page=3317
2. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998; 351: 1451-1467
3. Kennecke HF et al, Annals of Oncology. 2006 Oct 9; [epub ahead of print]
4. Sapher T et al. J Clin Oncol 1996; 14(10): 2738-2746
5. The GAEA Initiative. Gathering Information on Adjuvant Endocirne Therapy
|